

SUBSTITUTE FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER
06501-095001

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If Known, see 37 CFR
1.5) **10/009329**INTERNATIONAL APPLICATION NO.
PCT/JP00/03557INTERNATIONAL FILING DATE
1 June 2000PRIORITY DATE CLAIMED
1 June 1999TITLE OF INVENTION
PACKAGING CELLAPPLICANT(S) FOR DO/EO/US
Toshio Kitamura and Sumiyo Morita

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other documents or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:
 - Deposit Receipts and Verification of Translations for FERM BP-6737 and FERM BP-6977, 6 pgs.
 - Informal Sequence Listing, 6 pgs.
 -
 -
 -
 -

CERTIFICATE OF MAILING BY EXPRESS MAIL


Express Mail Label No **EL624321200US**

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

December 3, 2001
Date of Deposit

Signature

Hervy Jenkins
Typed Name of Person Signing

U.S. APPLICATION NO. (IF KNOWN) 10/009329	INTERNATIONAL APPLICATION NO. PCT/JP00/03557	ATTORNEY'S DOCKET NUMBER 06501-095001																				
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY																				
Basic National Fee (37 CFR 1.492(a)(1)- (5)):																						
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1040																						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890																						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$740																						
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$710																						
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100																						
ENTER APPROPRIATE BASIC FEE AMOUNT = \$890.00																						
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$0.00																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Claims</th> <th style="text-align: left;">Number Filed</th> <th style="text-align: left;">Number Extra</th> <th style="text-align: left;">Rate</th> <th style="text-align: left;"></th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>15 - 20 =</td> <td>0</td> <td>x \$18</td> <td>\$0.00</td> </tr> <tr> <td>Independent Claims</td> <td>2 - 3 =</td> <td>0</td> <td>x \$84</td> <td>\$0.00</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIMS(S) (if applicable)</td> <td>+ \$280</td> <td>\$0.00</td> </tr> </tbody> </table>			Claims	Number Filed	Number Extra	Rate		Total Claims	15 - 20 =	0	x \$18	\$0.00	Independent Claims	2 - 3 =	0	x \$84	\$0.00	MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$280	\$0.00
Claims	Number Filed	Number Extra	Rate																			
Total Claims	15 - 20 =	0	x \$18	\$0.00																		
Independent Claims	2 - 3 =	0	x \$84	\$0.00																		
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$280	\$0.00																		
TOTAL OF ABOVE CALCULATIONS = \$0.00																						
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. \$0.00																						
SUBTOTAL = \$890.00																						
Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) \$0.00																						
TOTAL NATIONAL FEE = \$890.00																						
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$0.00																						
TOTAL FEES ENCLOSED = \$890.00																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;"></td> <td style="width: 20%; text-align: center;">Amount to be refunded:</td> <td style="width: 20%; text-align: right;">\$</td> </tr> <tr> <td></td> <td style="text-align: center;">Charged:</td> <td style="text-align: right;">\$</td> </tr> </table>				Amount to be refunded:	\$		Charged:	\$														
	Amount to be refunded:	\$																				
	Charged:	\$																				
a. <input checked="" type="checkbox"/> A check in the amount of \$890.00 to cover the above fees is enclosed.																						
b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.																						
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.																						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.																						
SEND ALL CORRESPONDENCE TO:																						
Janis K. Fraser, Ph.D., J.D. FISH & RICHARDSON P.C. 225 Franklin Street Boston, Massachusetts 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile																						
 SIGNATURE : Janis K. Fraser, Ph.D., J.D. NAME _____ 34,819 REGISTRATION NUMBER _____																						

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Kitamura et al.
Serial No. :
Filed : Herewith
Title : PACKAGING CELL

Art Unit : Unknown
Examiner : Unknown

Box PCT

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Please amend the following paragraphs:


Page 14, lines 26-36 through page 15, lines 1-2:

-- Measurement of infection efficiencies of the virus solutions obtained from PLAT-E (ecoenv-introduced PLAT-E cells) and BOSC23, thawed simultaneously from liquid nitrogen, using BaF/3 cells revealed that the infection efficiencies after 7 days from the beginning of the passage was 90% or more for both packaging cells. On the other hand, after 2 months of passage, whereas the infection efficiency decreased to 23% when the BOSC23 (Pear et al., Proc. Natl. Acad. Sci. USA, 90:8392-8396, 1993) was used, infection efficiency as high as that after 7 days was confirmed to be maintained even after 2 months of passage, as well as after 4 months of passage (after 4 months from the beginning of the passage, infection efficiency of 70% or

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No EL624321200US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

Date of Deposit December 3, 2001
Signature 
Typed or Printed Name of Person Signing Certificate Leroy Jenkins

more was maintained towards BaF/3 cells) when PLAT-E was used. That is, for approximately 4 months it was possible to produce retroviruses at titers of approximately 1 x 10⁷/ml.--

Page 15, lines 30-36, through page 16, lines 1-16 as follows:

-- The present inventors compared Plat-E cells in its initial progress to Bosc23 cells and Phoenix-E (http://www.stanford.edu/group/nolan/tutorials/retpkg_7_phx_sys.html) (a tutorial of Phoenix ecotropic and amphotropic packaging lines on the web site of Nolan Laboratory in the Department of Molecular Pharmacology/the Department of Microbiology and Immunology in the School of Medicine at Stanford University)) cells in terms of its ability or inability to produce retroviruses at a high titer with long-term stability by transient transfection. The cultivation conditions for the three packaging cell lines were as follows:

According to the manufacturer's instructions, the Bosc23 cells were proliferated in DMEM containing GPT selective reagent (Specialty Media, Lavallette, NJ, USA) supplemented with 10% fetal bovine serum. Phoenix -E cells were classified by FACS using the expression of CD8 as an index, were cultured for one week in DMEM containing hygromycin (300 mg/ml) and diphtheria toxin (1 mg/ml) supplemented with 10% fetal bovine serum, and then were transferred to DEME supplemented with 10% bovine fetal serum which doesn't contain hygromycin and diphtheria toxin. Plat-E cells were maintained all the time in DEME containing blasticidin (10 mg/ml) and puromycin (1 mg/ml) supplemented with 10% fetal bovine serum . The infection efficiency of retroviruses produced from Bosc23 diminished within 3 months and that of retroviruses produced from Phoenix-E cells diminished similarly. On the other hand, retroviruses produced from Plat-E retained an average titer of approximately 1x 10⁷/ml to NIH3T3 cells for at least 4 months under conditions of drug selective pressure and an infection efficiency of 75% or more (maximum of 99%) to BaF/3 cells when they were transfected transiently. --

In the claims:

Amend claims 5-9, 12, 14 and 15 as follows:

-- 5. The cell according to claim 3, wherein the env is derived from either an ecotropic retrovirus or amphotropic retrovirus.

6. The cell according to claim 1, wherein a Kozak's consensus sequence is placed upstream of a translation initiation codon of the DNA encoding the retroviral structural proteins in the expression construct.

7. The cell according to claim 1, wherein the DNA encoding the retroviral structural proteins is bound to a DNA encoding a selective marker via an IRES sequence.

8. The cell according to claim 1, wherein the DNA encoding the retroviral structural proteins is substantially free from virus genome-derived DNA with the exception of the protein coding region.

9. The cell according to claim 1, wherein the cell is derived from 293 cells.

12. A method for producing a retrovirus, comprising the step of: introducing a retroviral vector DNA lacking at least one of the genes encoding a viral structural protein into the cell of claim 1.

14. The method according to claim 12, in which a foreign gene is included in the retroviral vector DNA.

15. A retrovirus produced by the method of claim 12.--

Applicant : Toshio Kitamura et al.
Serial No. :
Filed : Herewith
Page : 4

Attorney's Docket No.: 06501-095001


REMARKS

Claims 1 to 15 are pending in this application. Claims 5-6, 12, 14 and 15 have been amended to delete multiple dependency. No new matter has been added.

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all claims be examined. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20353023.doc

Version with markings to show changes made

In the specification:

Please amend the following paragraphs:

Page 14, lines 26-36 through page 15, lines 1-2:

Measurement of infection efficiencies of the virus solutions obtained from PLAT-E (ecoenv-introduced PLAT-E cells) and BOSC23, thawed simultaneously from liquid nitrogen, using BaF/3 cells revealed that the infection efficiencies after 7 days from the beginning of the passage was 90% or more for both packaging cells. On the other hand, after 2 months of passage, whereas the infection efficiency decreased to 23% when the BOSC23 (Pear et al., Proc. Natl. Acad. Sci. USA, 90:8392-8396, 1993) was used, infection efficiency as high as that after 7 days was confirmed to be maintained even after 2 months of passage, as well as after 4 months of passage (after 4 months from the beginning of the passage, infection efficiency of 70% or more was maintained towards BaF/3 cells) when PLAT-E was used. That is, for approximately 4 months it was possible to produce retroviruses at titers of approximately 1 x 10⁷/ml.

Page 15, lines 30-36, through page 16, lines 1-16 as follows:

The present inventors compared Plat-E cells in its initial progress to Bosc23 cells and Phoenix-E (http://www.stanford.edu/group/nolan/tutorials/retpkg_7_phx_sys.html (a tutorial of Phoenix ecotropic and amphotropic packaging lines on the web site of Nolan Laboratory in the Department of Molecular Pharmacology/the Department of Microbiology and Immunology in the School of Medicine at Stanford University)) cells in terms of its ability or inability to produce retroviruses at a high titer with long-term stability by transient transfection. The cultivation conditions for the three packaging cell lines were as follows:

According to the manufacturer's instructions, the Bosc23 cells were proliferated in DMEM containing GPT selective reagent (Specialty Media, Lavallette, NJ, USA) supplemented with 10% fetal bovine serum. Phoenix -E cells were classified by FACS using the expression of CD8 as an index, were cultured for one week in DMEM containing hygromycin (300 mg/ml) and diphtheria toxin (1 mg/ml) supplemented with 10% fetal bovine serum, and then were transferred

to DEME supplemented with 10% bovine fetal serum which doesn't contain hygromycin and diphtheria toxin. Plat-E cells were maintained all the time in DEME containing blasticidin (10 mg/ml) and puromycin (1 mg/ml) supplemented with 10% fetal bovine serum . The infection efficiency of retroviruses produced from Bosc23 diminished within 3 months and that of retroviruses produced from Phoenix-E cells diminished similarly. On the other hand, retroviruses produced from Plat-E retained an average titer of approximately 1x 10⁷/ml to NIH3T3 cells for at least 4 months under conditions of drug selective pressure and an infection efficiency of 75% or more (maximum of 99%) to BaF/3 cells when they were transfected transiently.

In the claims:

Claims 5-9, 12, 14 and 15 have been amended as follows:

5. The cell according to claim 3 [or 4], wherein the env is derived from either an ecotropic retrovirus or amphotropic retrovirus.
6. The cell according to [any one of claims 1 to 5] claim 1, wherein a Kozak's consensus sequence is placed upstream of a translation initiation codon of the DNA encoding the retroviral structural proteins in the expression construct.
7. The cell according to [any one of claims 1 to 6] claim 1, wherein the DNA encoding the retroviral structural proteins is bound to a DNA encoding a selective marker via an IRES sequence.
8. The cell according to [any one of claims 1 to 7] claim 1, wherein the DNA encoding the retroviral structural proteins is substantially free from virus genome-derived DNA with the exception of the protein coding region.
9. The cell according to [any one of claims 1 to 8] claim 1, wherein the cell is derived from 293 cells.

12. A method for producing a retrovirus, comprising the step of: introducing a retroviral vector DNA lacking at least one of the genes encoding a viral structural protein into the cell of [any one of claims 1 to 11] claim 1.

14. The method according to claim 12 [or 13], in which a foreign gene is included in the retroviral vector DNA.

15. A retrovirus produced by the method of [any one of claim 12 to 14] claim 12.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Kitamura et al.
Serial No. : 10/009,329
Filed : December 3, 2001
Title : PACKAGING CELL

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

In response to the communication dated February 19, 2002 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit a substitute Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.


In the specification:

Replace the original Sequence Listing with the substitute Sequence Listing filed herewith.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 940767121US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit 4-11-02Signature Typed or Printed Name of Person Signing Certificate Leroy Jenkins

Applicant : Toshio Kitamura et al.
Serial No. : 10/009,329
Filed : December 3, 2001
Page : 2


Attorney's Docket No.: 06501-095001 / C1-
105DP1PCT-US

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely replace the original paper copy of the Sequence Listing with an amended substitute Sequence Listing wherein the general information (i.e., attorney docket number, serial number, filing date) has been updated to reflect the general information of the instant application. No new matter has been added.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket no. 06501-095001.

Respectfully submitted,


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Date: April 11, 2002
Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20399286.doc

VERIFICATION OF TRANSLATION

I, Kazunori Hashimoto

of 6th Fl., Kantetsu Tsukuba-Science-City Bldg. 1-1-1, Oroshi-machi,
Tsuchiura, Ibaraki, JAPAN

declare as follows:

1. That I am well acquainted with both the English and Japanese languages, and
2. That the attached document is a true and correct translation made by me to the best of my knowledge and belief of the attached Deposit receipt which is in the Japanese language.

November 26, 2001

(Date)

Kazunori Hashimoto

(Signature of Translator)

Kazunori Hashimoto

Patent Attorney

SEQUENCE LISTING

<110> KITAMURA, Toshio

<110> CHUGAI SEIYAKU KABUSHIKI KAISHA

<120> Packaging cell

<130> C1-105DP1PCT

<140>

<141>

<150> JP 1999-154364

<151> 1999-06-01

<150> JP 2000-17831

<151> 2000-01-21

<160> 11

<170> PatentIn Ver. 2.0

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 1

aaaacattta acatttctca acaag 25

<210> 2

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 2

acgcgtcgac ttaatttcgg gtatatttga gtg 33

<210> 3

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 3

accgagtaca agcccacg 18

<210> 4

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 4

acgcagatct tcaggcacccg ggcttg 26

<210> 5

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 5

cgaattcgcc gccaccatgg gccagactgt taccactccc ttAA 44

<210> 6

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 6

tacgccccgc ctctgagcat cagaagaa 28

<210> 7

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 7

cgaattcgcc gccaccatgg cgcggttcaac gctctcaaaa 40

<210> 8

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 8

tacgcccggcg ctatggctcg tactctat 28

<210> 9

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized "Sall linker" Sequence

<400> 9

cggtcgacccg 10

<210> 10

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 10

cgaattcgcc gccaccatgg cgcggttcaac gctctcaaaa 40

<210> 11

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificially
Synthesized Primer Sequence

<400> 11

atgcggccgc tcatggctcg tactctat 28

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Kitamura et al.
Serial No. : 10/009,329
Filed : December 3, 2001
Title : PACKAGING CELL

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Katica Magovcevic, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 3/6/02

Katica Magovcevic

Katica Magovcevic

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
(617) 542-5070 telephone
(617) 542-8906 facsimile

20396905.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 940767121US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit 4-11-02

Signature Harvey Jenkins

Typed or Printed Name of Person Signing Certificate Harvey Jenkins

SEQUENCE LISTING

<110> Kitamura, Toshio
Morita, Sumiyo

<120> PACKAGING CELL

<130> 06501-095001

<140> US 10/009,329

<141> 2001-12-03

<150> PCT/JP00/03557

<151> 2000-06-01

<150> JP 1999-154364

<151> 1999-06-01

<150> JP 2000-17831

<151> 2000-01-21

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Primer Sequence

<400> 1

aaaacattta acatttctca acaag

25

<210> 2

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Primer Sequence

<400> 2

acgcgtcgac ttaatttcgg gatatattga gtg

33

<210> 3

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Primer Sequence

<400> 3

accgagtaca agcccacg	18
<210> 4	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Artificially Synthesized Primer Sequence	
<400> 4	
acgcagatct tcaggcaccc ggcttg	26
<210> 5	
<211> 44	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Artificially Synthesized Primer Sequence	
<400> 5	
cgaattcgcc gccaccatgg gccagactgt taccactccc ttaa	44
<210> 6	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Artificially Synthesized Primer Sequence	
<400> 6	
tacgcccccg ctctgagcat cagaagaa	28
<210> 7	
<211> 40	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Artificially Synthesized Primer Sequence	
<400> 7	
cgaattcgcc gccaccatgg cgcgttcaac gctctcaaaa	40
<210> 8	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Artificially Synthesized Primer Sequence	
<400> 8	
tacgcccccg ctatggctcg tactctat	28

<210> 9
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Artificially Synthesized "SalI linker" Sequence

<400> 9
cggtcgaccg 10

<210> 10
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Primer Sequence

<400> 10
cgaattcgcc gccaccatgg cgcggttcaac gctctcaaaa 40

<210> 11
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Primer Sequence

<400> 11
atgcggccgc tcatggctcg tactctat 28



PCT10

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/009,329

DATE: 05/21/2002
TIME: 15:20:20

Input Set : A:\06501-095001.TXT
Output Set: N:\CRF3\05212002\J009329.raw

ENTERED

```

4 <110> APPLICANT: Kitamura, Toshio
5 . Morita, Sumiyo
7 <120> TITLE OF INVENTION: PACKAGING CELL
9 <130> FILE REFERENCE: 06501-095001
11 <140> CURRENT APPLICATION NUMBER: US 10/009,329
12 <141> CURRENT FILING DATE: 2001-12-03
14 <150> PRIOR APPLICATION NUMBER: PCT/JP00/03557
15 <151> PRIOR FILING DATE: 2000-06-01
17 <150> PRIOR APPLICATION NUMBER: JP 1999-154364
18 <151> PRIOR FILING DATE: 1999-06-01
20 <150> PRIOR APPLICATION NUMBER: JP 2000-17831
21 <151> PRIOR FILING DATE: 2000-01-21
23 <160> NUMBER OF SEQ ID NOS: 11
25 <170> SOFTWARE: FastSEQ for Windows Version 4.0
27 <210> SEQ ID NO: 1
28 <211> LENGTH: 25
29 <212> TYPE: DNA
30 <213> ORGANISM: Artificial Sequence
32 <220> FEATURE:
33 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
35 <400> SEQUENCE: 1
36 aaaacatcta acatattctca acaag 25
38 <210> SEQ ID NO: 2
39 <211> LENGTH: 33
40 <212> TYPE: DNA
41 <213> ORGANISM: Artificial Sequence
43 <220> FEATURE:
44 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
46 <400> SEQUENCE: 2
47 acgcgtcgac ttaatttcgg gtatatttga gtg 33
49 <210> SEQ ID NO: 3
50 <211> LENGTH: 18
51 <212> TYPE: DNA
52 <213> ORGANISM: Artificial Sequence
54 <220> FEATURE:
55 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
57 <400> SEQUENCE: 3
58 accgagtaca agccccacg 18
60 <210> SEQ ID NO: 4
61 <211> LENGTH: 26
62 <212> TYPE: DNA
63 <213> ORGANISM: Artificial Sequence
65 <220> FEATURE:

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/009,329

DATE: 05/21/2002
TIME: 15:20:20

Input Set : A:\06501-095001.TXT
Output Set: N:\CRF3\05212002\J009329.raw

66 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
 68 <400> SEQUENCE: 4
 69 acgcagatct tcaggcaccg ggcttg 26
 71 <210> SEQ ID NO: 5
 72 <211> LENGTH: 44
 73 <212> TYPE: DNA
 74 <213> ORGANISM: Artificial Sequence
 76 <220> FEATURE:
 77 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
 79 <400> SEQUENCE: 5
 80 cgaattcgcc gccaccatgg gccagactgt taccactccc ttaa 44
 82 <210> SEQ ID NO: 6
 83 <211> LENGTH: 28
 84 <212> TYPE: DNA
 85 <213> ORGANISM: Artificial Sequence
 87 <220> FEATURE:
 88 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
 90 <400> SEQUENCE: 6
 91 tacgccggcg ctctgagcat cagaagaa 28
 93 <210> SEQ ID NO: 7
 94 <211> LENGTH: 40
 95 <212> TYPE: DNA
 96 <213> ORGANISM: Artificial Sequence
 98 <220> FEATURE:
 99 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
 101 <400> SEQUENCE: 7
 102 cgaattcgcc gccaccatgg cgcgttcaac gctctaaaa 40
 104 <210> SEQ ID NO: 8
 105 <211> LENGTH: 28
 106 <212> TYPE: DNA
 107 <213> ORGANISM: Artificial Sequence
 109 <220> FEATURE:
 110 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
 112 <400> SEQUENCE: 8
 113 tacgccggcg ctatggctcg tactctat 28
 115 <210> SEQ ID NO: 9
 116 <211> LENGTH: 10
 117 <212> TYPE: DNA
 118 <213> ORGANISM: Artificial Sequence
 120 <220> FEATURE:
 121 <223> OTHER INFORMATION: Artificially Synthesized "Sall linker" Sequence
 123 <400> SEQUENCE: 9
 124 cggtcgaccg 10
 126 <210> SEQ ID NO: 10
 127 <211> LENGTH: 40
 128 <212> TYPE: DNA
 129 <213> ORGANISM: Artificial Sequence
 131 <220> FEATURE:
 132 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/009,329

DATE: 05/21/2002
TIME: 15:20:20

Input Set : A:\06501-095001.TXT
Output Set: N:\CRF3\05212002\J009329.raw

134 <400> SEQUENCE: 10
135 cgaattcgcc gccaccatgg cgcggtcaac gctctcaaaa 40
137 <210> SEQ ID NO: 11
138 <211> LENGTH: 28
139 <212> TYPE: DNA
140 <213> ORGANISM: Artificial Sequence
142 <220> FEATURE:
143 <223> OTHER INFORMATION: Artificially Synthesized Primer Sequence
145 <400> SEQUENCE: 11
146 atgcggccgc tcatggctcg tactctat 28

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/009, 329

DATE: 05/21/2002

TIME: 15:20:21

Input Set : A:\06501-095001.TXT

Output Set: N:\CRF3\05212002\J009329.raw

10/009329

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: PACKAGING CELL

APPLICANT: TOSHIO KITAMURA AND SUMIYO MORITA

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL624321200US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

December 3, 2001

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

10/009329

DESCRIPTION

PACKAGING CELL

5 Technical Field

The present invention relates to a virus-producing cell (packaging cell) that stably retains the ability to produce high titer viruses and the use of such a cell for virus production.

10 Background Art

Retroviral vectors are capable of transferring genes with high efficiency and stability to host cells. Thus, they are used in gene transfer methods, for transferring genes into cells in a variety of fields including the field of medicine. Generation of retroviral vectors has been developed based on the genetic structure and the life cycle mechanism of retroviruses. The fundamental principle is to transfer the gene of interest into a retroviral vector possessing a packaging signal but lacking each of the gag, pol, and env structural genes, then introducing the retroviral vector into a packaging cell possessing each of the gag, pol, and env structural genes lacking a packaging signal. Then, a virus particle containing the retroviral vector RNA is formed (i.e. packaged), and finally, retroviruses are produced into the supernatant of a cell culture (Kitamura, T., International Journal of Hematology, 67:351-359 (1998)).

25 Retroviruses produced in this manner can efficiently transfer the genes of interest into cells. Simultaneously, since they lack each of the gag, pol, and env structural genes, they can replicate only within the packaging cells and cannot replicate within normal cells. Therefore, functional retroviruses are unlikely to regenerate from

30 the prepared infected cells.

The production of packaging cells with such characteristics is disclosed in international publication numbers WO90/02806, WO94/19478, WO96/34098, and so on. However, the prior art is unsatisfying in terms of infection efficiency and long-term stability. In addition,

35 to increase the titer of the viruses, it is necessary to express the viral structural proteins in a large amount within the packaging cell.

Packaging cells that can express a large amount of viral structural proteins and show a limited reduction in titer of viruses produced through passages are needed in the art.

5 Disclosure of the Invention

The object of this invention is to provide a virus-producing cell having the ability to produce infectious viruses at high titers. In a preferred embodiment of the present invention, virus-producing cells with enhanced long-term stability and safety are provided.

10 Another object of this invention is to provide a method for producing infectious viruses at high titers using the virus-producing cells.

To accomplish the objects described above, the present inventors first searched for a promoter having a high activity in 293T cells. Upon investigating the strength of transcription activity of the SV40 promoter, SR α promoter, EF1 α promoter, TK promoter, MuLV LTR, and CMV LTR, the present inventors found that the activities driven by the EF1 α promoter and the CMV promoter were remarkably high compared to those of the other promoters. Accordingly, an attempt was made to establish high-performance packaging cells using the EF1 α promoter.

Specifically, the present inventors used only coding sequence for the gag-pol and env genes in the packaging constructs under the regulation of the EF1 α promoter in order to enhance the expression efficiency of the genes encoding the viral structural proteins in the packaging cells. Furthermore, to enhance the translation efficiency of the viral structural proteins from the transcribed mRNAs, Kozak's consensus sequence (GCCACC) was inserted upstream of the translation initiation codon of these genes. In addition, a selective marker resistant gene was linked via the IRES sequence (internal ribosomal entry site) downstream of these genes, so that the genes positioned upstream and downstream of the IRES are translated from a single mRNA. This enabled reliable selection of cells expressing the inserted construct by the selective marker. In this manner, cells were produced having superior long-term stability compared to conventional packaging cells by separately introducing a construct containing the selective marker resistant gene and, a construct containing the gag-pol and env genes.

In addition, improvement in safety was achieved by inserting the gag-pol and env genes produced by PCR amplification of only the viral structural proteins encoding regions into the construct, thus eliminating the possibility of emergence of wild type viruses from 5 the packaging cells due to recombination.

The present inventors examined the performance of the packaging cells produced in this manner and found out that the packaging cells produced high-titer retroviruses. Even after a long-term passage of 4 months, they retained the ability to produce retroviruses at the 10 same level of titer as before. The packaging cells of this invention are useful for producing vectors for gene transfer to a living body, and may be preferably utilized especially for producing high-titer retroviral vectors used for gene therapy, and such.

That is, the present invention relates to methods for producing 15 a virus-producing cell having superior safety, retaining the ability to produce infectious viruses at high titer even after long-term passages, and to methods for producing infectious viruses at high titer using the virus producing cells. More specifically, this invention provides the following:

- 20 (1) a cell for the production of retroviruses, wherein the cell has an expression construct comprising a DNA encoding retroviral structural proteins operably linked downstream of an EF1 α promoter;
- (2) the cell according to (1), wherein the DNA encoding retroviral structural proteins is a DNA encoding any one or more of the proteins selected from the group consisting of gag, pol, and env;
- (3) the cell according to (2) that expresses all of gag, pol, and env;
- 30 (4) the cell according to (3), which has an expression construct expressing gag and pol, and an expression construct expressing env;
- (5) the cell according to (3) or (4), wherein the env is derived from either an ecotropic retrovirus or amphotropic retrovirus;
- 35 (6) the cell according to any one of (1) to (5), wherein a Kozak's consensus sequence is placed upstream of the translation

initiation codon of the DNA encoding the retroviral structural proteins in the expression construct;

- (7) the cell according to any one of (1) to (6), wherein the DNA encoding the retroviral structural proteins is bound via the IRES sequence to a DNA encoding a selective marker;
- 5 (8) the cell according to any one of (1) to (7), wherein the DNA encoding the retroviral structural proteins is substantially free of virus genome-derived DNA with the exception of the protein coding region;
- H0 (9) the cell according to any one of (1) to (8), wherein the cell is derived from 293 cells;
- D0 (10) the cell according to (9), wherein the cell is derived from 293T cells;
- 15 (11) the cell specified by the accession No. FERM BP-6737 or FERM BP-6977;
- D0 (12) a method for producing a retrovirus, comprising the steps of: introducing a retroviral vector DNA lacking at least one of the genes encoding a viral structural protein into the cell of any one of (1) to (11);
- 20 (13) the method according to (12), wherein the retroviral vector DNA lacks all of the genes encoding the gag, pol, and env;
- (14) the method according to (12) or (13), wherein a foreign gene is included in the retroviral vector DNA; and
- (15) a retrovirus produced by the method of any one of (12) to (14).

25 The packaging cells of this invention are characterized by their use of the EF1 α promoter for the expression of retroviral structural proteins. The present inventors searched for a promoter that has a high activity in packaging cells. As a result, it was found out that the EF1 α promoter had an especially strong activity among the promoters whose activity could be detected. The packaging cells of this invention highly-express the retroviral structural protein due to the use of the EF1 α promoter, which, in turn, enables the production of high-titer virus particles.

30 A DNA encoding the retroviral structural protein(s) is expressed under the regulation of the EF1 α promoter in a packaging cell by producing an expression construct in which the DNA encoding the

retroviral structural protein(s) is operably linked downstream of the EF1 α promoter, and then, introducing it into the cell. The term "operably linked" used herein indicates that the EF1 α promoter is bound to the DNA such that its activation ensures the expression of the downstream DNA encoding the retroviral structural protein.

Examples of the retroviral structural proteins expressed in the cells are the gag, pol, and env. Theoretically, it is not necessary to express all of these proteins in the packaging cells and it is possible to place genes encoding some of these proteins on the retroviral vector DNA. For example, it is possible to have the packaging cells express the gag and pol, whereas the env gene is placed on the retroviral vector DNA. However, in this case, there is the possibility that the amount of env expression would not reach the required amount. Therefore, it is preferable that all of gag, pol, and env are expressed by the packaging cells themselves.

The expression construct is preferably separated into a construct expressing the gag and pol, and a construct expressing the env, which are then introduced into the cell. In this manner, the possibility that self-replicating viruses will be produced, due to the recombination of pol, gag, and env that often occurs among those existing on the retroviral vector and those in the packaging cell, will be reduced. This is important from the view of safety, for example, when using the viruses produced by these cells in gene therapy. Regarding gag and pol, it is preferable to have them encoded as gag-pol on a same construct. This is because it is known that the expression ratio between pol and gag is important for the production of high-titer viruses and expression of pol alone at large quantities, which may occur by making separate expression constructs of gag and pol, will cause toxicity towards the cell.

It is possible to prepare packaging cells using env, if desired, derived from ecotropic retroviruses (referred to as ecoenv) or amphotropic retroviruses (referred to as amphoenv). Packaging cells having ecoenv produce ecotropic retroviruses whereas packaging cells having amphoenv produce amphotropic retroviruses. Since the ecotropic retrovirus has a glycoprotein binding to the ecotropic receptor that exists only on the cell surface of rat and mouse, they

only infect rat and mouse cells. On the other hand, the amphotropic retrovirus is capable of infecting various species, such as rat, mouse, humans, chicken, dog, cat, etc. An example of a retrovirus used in gene therapy is the amphoenv, which is capable of infecting humans. 5 However, to clone novel genes in the laboratory, it is safer to use retroviruses produced from packaging cells that carry ecoenv with no infectivity to human.

Various retroviral env, such as env derived from Rous sarcoma virus (RSV), may be used (Landau, N.R. and Littman, D.R., (1992) J. Virology 5110-5113)). Furthermore, envelope proteins other than those from retroviruses may be used. For example, it is possible to use vesicular stomatitis virus (VSV)-derived G protein (VSV-G) (Ory, D.S. et al., (1996) Proc. Natl. Acad. Sci. USA 93: 11400-11406).

In a preferred embodiment of this invention, the Kozak's consensus sequence (GCCACC) is placed upstream of the translation initiation codon (ATG) of the retroviral structural protein gene within the expression construct to increase the translation efficiency of mRNA encoding these proteins transcribed from the expression constructs for expression of retroviral structural proteins (the 20 Kozak's rule reveals that it is highly probable that a GCCACC sequence exists in front of the translation initiation site ATG).

In another preferred embodiment, this invention provides packaging cells harboring expression constructs that express the viral structural protein(s) and a selective marker simultaneously by operably linking the DNA encoding the viral structural protein(s) and selective marker via the IRES. The viral structural protein(s) and selective marker are encoded on a single molecule transcribed by EF1 α activation in the expression construct. Thus, not only the protein(s) but also the selective marker is translated by the action 25 of IRES from the RNA molecule. Accordingly, reliable selection of cells expressing the retroviral structural protein(s) by the selective marker becomes possible due to the transformation with the expression construct. Conventionally, packaging cells were produced by separately introducing an expression construct carrying the selective 30 marker resistant gene and an expression construct carrying the gag-pol and env genes into cells. Thus, the cells harboring the selective 35

marker resistant gene and those harboring the viral structural protein genes were not always consistent, which caused problems in terms of the stability of the cells. The utilization of the IRES sequence enables the preparation of packaging cells with excellent long-term

5 stability.

In addition to blasticidin and puromycin described in the examples, for example, hygromycin, diphtheria toxin, neomycin, and such may be used as selective markers. However, blasticidin and puromycin are preferable since they act quickly and require shorter
10 time for selection of cells as compared to other drugs. The resistant genes of diphtheria toxin and hygromycin are described in "Bishai,
15 W.R. et al., J. Bacteriol., 169: 1554-1563 (1987)" and "hygromycin:
Yin, D.X. et al., Cancer Res., 55: 4922-4928 (1995)", respectively.

In a further preferred embodiment, this invention provides cells
20 harboring an expression construct in which the DNA encoding retroviral structural protein(s) under the regulation of EF1 α is substantially free of DNA other than that of the protein coding region. In the packaging cells of this invention, it is preferable to maximally remove viral genome-derived sequences that are not essential for expression
25 of structural proteins. This allows one to cut down to a minimum the risk of emergence of replication-capable retroviruses (RCR) by reducing the possibility of recombination between the viral genome-derived DNA and retroviral DNA within the expression construct after the retroviral vector DNA is transferred into packaging cells
30 that have above-mentioned expression constructs. This, in turn, enables improvement of the safety of the virus particles produced from the packaging cells.

DNA that is substantially free of DNA, other than that of such retroviral structural protein coding regions, may be obtained, for example, by a polymerase chain reaction using the viral genome DNA as the template and primers corresponding to the viral structural protein coding regions as described in the following examples. Herein, "is substantially free of" DNA other than that of the coding region means that DNA other than that of the viral genome-derived protein
35 coding region is 30 or less, preferably 10 or less, more preferably 5 or less, and most preferably 0 bases.

For example, NIH3T3 (mouse fibroblast), 293 (human fetal kidney cells) (Graham, F.L., J. Gen. Virol., 36, 59-72 (1977)), and such may be used as host cells for the production of packaging cells. However, the invention is not limited thereto, so long as the cells have a
5 high transfection efficiency.

The calcium phosphate method, electroporation method, and general transfection methods with lipofectamine (GIBCO BRL), Eugene (Boehringer Mannheim), and such may be used to introduce expression constructs into the cell. Drug selection may be used as the selection method. For example, blasticidin, puromycin, hygromycin, diphtheria toxin, neomycin, and such may be used as the drug for drug selection, without limitation so long as the drug tolerance gene is known.
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

Preferably, the retroviral vector DNA is introduced into each clone of the obtained packaging cells following limiting dilution of the cells. Then, through measurement of the titer of the produced viruses, cells producing viruses with the highest titer are selected and cloned.

There is no particular limitation on the retroviral vector DNA inserted into the packaging cells. When the packaging cells are derived from cells expressing the SV40 large T antigen, as in the 293T cells, the use of vector DNA bound to the replication initiation site of SV40 enables an increase in the number of its copies produced within the packaging cells, and thus an increase in titer can be expected.
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

Introduction of retroviral vector DNA into cells can be carried out by the same method as that described above for the introduction of the viral structural protein expression constructs into cells. The retroviral vector of interest can be prepared by harvesting the retroviral particles released into the supernatant of the packaging cell culture after the introduction of the retroviral vector.
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

The retroviral vectors produced by the packaging cells of this invention may be utilized in comprehensive fields of research and medicine. For example, they may be used as vectors for expressing the gene of interest ex vivo or in vivo in gene therapy and in the production of animal models. They may be also useful as vaccines, for expressing antigenic proteins and proteins that elevate immunological functions. Further, they may be also useful as *in vitro*
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

gene transfer vectors for analyzing gene functions. Further, the vectors can be also used to produce proteins of interest. They are also useful as vectors for production of a library that expresses nonspecific cDNA molecule species, such as a cDNA expression library.

5

Best Mode for Carrying Out the Invention

The present invention will be specifically described by way of examples as follows. However, this invention should not be limited
10 to these examples.

[Example 1] FACS-GAL analysis

FACS-GAL analysis (Steven, N.F. et al., Cytometry, 12, 291-301, 1991) was performed in order to utilize the promoter exhibiting the highest activity, by comparing promoter activities in 293 cells and 293T cells. According to the method, each of the promoters to which the lacZ gene was linked downstream were transfected into cells, and the expression distribution of lacZ within those cells was investigated.

20 293 cells and 293T cells were plated at 2×10^6 cells per 6-cm tissue culture dish, 16 to 24 hours before transfection. 3 μ g of plasmid, having lacZ linked downstream of each of the promoters, and 9 μ l of Fugene (Boehringer Mannheim) were mixed into 200 μ l fetal bovine serum-free DMEM medium, then were left standing for 5~10 minutes.

25 Thereafter, the plasmids were gently added to the 6-cm dishes plated with either 293 cells or 293T cells. The cells were removed after 24 hours, and then were suspended into 50 μ l PBS, followed by incubation at 37°C for 5 minutes. Then, 50 μ l FDG (fluorescein di-b-D-galactopyranoside, Molecular Probe, Eugene, OR, catalog No.

30 F1179: 2 mM in 98% distilled water) pre-warmed at 37°C was added.

After incubation at 37°C for 1 minute, 1 ml PBS was added and the cells were placed on ice for 2 hours. After 2 hours, 20 μ l PETG (phenyl ethyl-b-D-thiogalactoside, Sigma, catalog No. P4902) was added to stop the reaction, and the expression distribution of lacZ within 35 the cell was investigated by FACS. As a result, the promoter activity of EF1 α was determined to be the highest in 293T cells. Compared to

the retroviral promoter, LTR, the promoter activity of EF1 α was approximately 100-fold higher, and compared to other promoters, the activity was tens of times higher.

5 [Example 2] Amplification of the Selective marker gene

To use blasticidin and puromycin as the selective markers, PCR reaction was carried out under the following conditions using the resistant genes of each markers (bs^r: Kamakura, T. et al., Agric. Biol. Chem., 51, 3165-3168, 1987; puro^r: Buchholz, F. et al., Nucleic Acids Res., 24, 3118-3119, 1996) as the templates.

The reaction mixture consisted 10 ng template DNA, 5 μ l 10x KOD buffer, 5 μ l 2 mM dNTP, 2.5 μ l of each 10 μ M primers (the base sequence of the primers are shown below), 2 μ l 25 mM MgCl₂, and 1 μ l 2.5 U/ml KOD DNA polymerase (TOYOBO).

15 The primers used for the blasticidin resistant gene (bs^r) were 5'-AAACATTTAACATTCTAACAAAG-3' (SEQ ID NO: 1) and 5'-ACGCGTCGACTTAATTCGGGTATATTGAGTG-3' (SEQ ID NO: 2), and those for the puromycin resistant gene (puro^r) were 5'-ACCGAGTACAAGCCCACG-3' (SEQ ID NO: 3) and 5'-ACGCAGATCTCAGGCACCAGGGCTTG-3' (SEQ ID NO: 4). 20 The temperature conditions were 94°C for 30 seconds, 25 cycles of 94°C for 30 seconds · 54°C for 30 seconds · 72°C for 2 minutes, and 72°C for 10 minutes. After restriction enzyme treatment of the blasticidin resistant gene (bs^r) with SalI and the puromycin resistant gene (puro^r) with BglII, electrophoresis followed by extraction from 25 the gel was performed. QiaexII (QIAGEN) was used for the extraction.

[Example 3] Preparation of pMX-IRES-EGFP

30 The IRES (internal ribosomal entry site) sequence is a sequence existing in the 5'-noncoding region of the viral mRNA, and is thought to form a characteristic secondary structure. Protein translation of the host is inhibited due to the recognition of this sequence by the ribosome that initiates translation, which allows a predominant translation of the viral protein. To link the selective marker 35 resistant gene behind the IRES, pMX-IRES-EGFP (Nosaka, T. et al., EMBO J., 18, 4754-4765, 1999) was digested with NcoI. After ethanol precipitation, blunt ends were made via Klenow reaction. After

phenol/chloroform treatment and ethanol precipitation thereafter, restriction enzyme treatment with SalI to insert bs^r, or treatment with BglII to insert puro^r was carried out followed by ligations of each construct. Thus, the selective marker resistant gene was positioned behind the IRES. IRES-bs^r fragment was cut out from pMX-IRES-bs^r by digesting with NotI (TAKARA) and SalI, while IRES-puro^r fragment was cut out from pMX-IRES-puro^r with NotI and BglII.

[Example 4] Amplification of gag-pol and ecotropic env

PCR for gag-pol and ecotropic env were performed under the following conditions.

The reaction mixture consisted 10 ng template DNA (Shinnick, et al., Nature, 293, 543, 1981), 5 µl 10x LA Taq buffer, 8 µl 2 mM dNTP, 1 µl of each 10 µM primers (the nucleotide sequences are shown below), and 0.5 µl 5 U/ml LA Taq (TAKARA).

The primers used for amplification of gag-pol were 5'-CGAATTCGCCGCCACCATGGGCCAGACTGTTACCACTCCCTAA-3' (SEQ ID NO: 5) and 5'-TACGCCGGCGCTCTGAGCATCAGAAGAA-3' (SEQ ID NO: 6), and those used for amplification of ecotropic env were 5'-CGAATTCGCCGCCACCATGGCGCGTTAACGCTCTAAAAA-3' (SEQ ID NO: 7) and 5'-TACGCCGGCGCTATGGCTCGTACTCTAT-3' (SEQ ID NO: 8).

The temperature conditions for gag-pol were 98°C for 2 minutes, 20 cycles of 98°C for 20 seconds · 68°C for 3 minutes, and 68°C for 8 minutes. Those for ecotropic env were 98°C for 2 minutes, 30 cycles of 98°C for 20 seconds · 68°C for 2 minutes, and 68°C for 7 minutes.

After electrophoresis of the PCR products, DNAs were extracted from the gel with QiaexII (QIAGEN). These DNAs were subcloned into TA vectors using the Original TA cloning kit (Invitrogen), and were digested with EcoRI and NotI (TAKARA).

[Example 5] Construction of gag-pol expression vector and ecotropic env expression vector

To express either gag-pol-IRES-bs^r or env-IRES-puro^r under the control of EF1α, the respective sequences were inserted into pCHO (Hirata, Y. et al., FEBS Letter, 356, 244-248 (1994); Okayama, Y. et al., Biochem. Biophys. Res. Commun., 838-45 (1996); pCHO is derived

from pEF-BOS (Mizushima, S. and Nagata, S., Nucleic Acids Res., 18, 5332, (1990)) as described below.

[pCHO(gag-pol-IRES-bs^r)]

After restriction enzyme treatment of pCHO with BamHI (TAKARA), blunt ends were produced via Klenow reaction. Following ligation to the SalI linker d(CGGTCGACCG) (Stratagene) (SEQ ID NO: 9), it was digested with EcoRI and SalI (TAKARA). The gag-pol and IRES-bs^r fragments produced in Examples 2 and 3 were inserted to produce pCHO (gag-pol-IRES-bs^r).

[pCHO(ecoenv-IRES-puro)]

After restriction enzyme treatment of pCHO with EcoRI and BamHI (TAKARA), ecotropic env and IRES-puro^r produced in Examples 2 and 3 were inserted to produce pCHO (ecoenv-IRES-puro).

[Example 6] Construction of amphotropic env expression vector

While ecotropic env can infect only those cells derived from the same species, amphotropic env can infect a variety of cells. Using this amphotropic env, the env-IRES-puro^r expression vector was constructed as in Examples 4 and 5. The reaction mixture was contained 10 ng plasmid in which the amphotropic env gene (4070A) (Ott, D. et al., J. Virol. 64. 757-766, 1990) was inserted, 5 μl 10x KOD buffer, 5 μl 2 mM dNTP, 2.5 μl of each 10 μM primers (the nucleotide sequences are shown below), 2 μl 25 mM MgCl₂, and 1 μl 2.5 U/ml KOD DNA polymerase (TOYOBO). 5'-CGAATTGCCGCCACCATGGCGCGTTAACGCTCTCAAAA-3' (SEQ ID NO: 10) and 5'-ATGCAGCCGCTCATGGCTCGTACTCTAT-3' (SEQ ID NO: 11) were used as primers. The temperature conditions were 98°C for 3 minutes, 25 cycles of 98°C for 15 seconds · 65°C for 2 seconds · 72°C for 30 seconds, and 72°C for 10 minutes.

pCHO (ecoenv-IRES-puro) produced in Example 5 was digested with EcoRI and NotI, and blunted via Klenow treatment. The amphotropic env above was then ligated to produce pCHO(amphoenv-IRES-puro).

[Example 7] Establishment of packaging cells

The 293T cells derived from human mesonephric cells, (DuBridge, R.B. et al., Mol. Cell. Biol., 7, 379-387. 1987) were transfected with the prepared construct. The 293T cells were plated at 2x 10⁶

cells per 6-cm tissue culture dish, 16~24 hours before transfection. 3 µg pCHO (gag-pol-IRES-bs^r) and 9 µl Fugene (Boehringer Mannheim) were mixed with 200 µl fetal bovine serum-free DMEM media, and the mixture was left standing for 5 to 10 minutes. Then, the mixture was
5 gently added to the 6-cm dish plated with 293T cells. Cells were removed 48 hours later, plated onto a 10-cm dish, and were added to them DMEM media containing 10% fetal bovine serum (8 µg/ml blasticidin).

Approximately 10 days later, each of pCHO (ecoenv-IRES-puro) and pCHO (amphoenv-IRES-puro) were transfected similarly, and then were cultured in a medium containing both of puromycin (0.8 µg/ml) and blasticidin (8 µg/ml). The packaging cells of interest were established by obtaining single clones by limiting dilution at the time when proliferation of the cells had occurred.

The packaging cell in which the ecoenv expression vector was introduced was named "Platinum-E cell (PLAT-E cell)". The cell was deposited as "Pt-E" to a depositary institution as described below.

(a) Name and address of the depositary institution

Name: National Institute of Bioscience and Human-Technology,
Agency of Industrial Science and Technology

Address: 1-1-3 Higashi, Tsukuba-shi, Ibaraki, Japan (Postal code
number: 305-8566)

(b) Date of deposition (Date of original deposition): May 31, 1999

(c) Accession number: FERM BP-6737

Moreover, the packaging cell in which the amphoenv expression vector was introduced was named "Platinum-A cell (PLAT-A cell)". The cell was deposited as "Plat-A" to a depositary institution as described below.

(a) Name and address of the depositary institution

Name: National Institute of Bioscience and Human-Technology,
Agency of Industrial Science and Technology

Address: 1-1-3 Higashi, Tsukuba-shi, Ibaraki, Japan (Postal code
number: 305-8566)

(b) Date of deposition (Date of original deposition): December 22,
1999

35 (c) Accession number: FERM BP-6977

[Example 8] Production of retroviruses

To investigate the infection efficiency of the viral solution obtained from the packaging cells, an infection experiment was performed by the following method. Packaging cells (ecoenv-introduced PLAT-E cells) were plated at 2×10^6 cells per 6-cm tissue culture dish, 16 to 24 hours before transfection. 3 μg vector DNA (pMX-GFP: Onishi, M. et al., Exp. Hematol., 24, 324-329, 1996), which is a retroviral vector carrying MoLuLV as its basic framework and to which GFP is inserted, and 9 μl Fugene were mixed with 200 μl serum-free DMEM media, and was left standing for 5 to 10 minutes. This was then added gently to the 6-cm dish plated with the packaging cells.

H10
D
G
G
S
E
215
R
D
P
P
R
D
20
lightatawavelengthof395nm andcauseemissionoflightatawavelength
of 509 nm, infection efficiency was measured as the proportion of
cells emitting light (i.e. infectively expressing) using FACScan
(fluoresceinactivatedcellsorter:Becton-Dickinson). The infection
efficiency towards BaF/3 cells reached 95%, even without concentration
25 of the virus solution.

Measurement of infection efficiencies of the virus solutions obtained from PLAT-E (ecoenv-introduced PLAT-E cells) and BOSC23, thawed simultaneously from liquid nitrogen, using BaF/3 cells revealed that the infection efficiencies after 7 days from the beginning of the passage was 90% or more for both packaging cells. On the other hand, after 2 months of passage, whereas the infection efficiency decreased to 23% when the BOSC23 was used, infection efficiency as high as that after 7 days was confirmed to be maintained even after 2 months of passage, as well as after 4 months of passage (after 4 months from the beginning of the passage, infection efficiency of 70% or more was maintained towards BaF/3 cells) when PLAT-E was used.

That is, for approximately 4 months it was possible to produce retroviruses at titers of approximately $1 \times 10^7/\text{ml}$.

When the infection efficiency of virus solution obtained from PLAT-A cells was measured using BaF/3 cells, a value of 30% was confirmed
5 on the 7th day from passage initiation (titer of approximately $1 \times 10^6/\text{ml}$).

[Example 9] Examination on the safety of PLAT-E

It was examined whether retroviruses, which have acquired the ability to replicate due to recombination (RCR; replication competent retroviruses), appeared or not while the retrovirus vectors were introduced to the cells.

16 hours after 5×10^4 NIH3T3 cells were plated onto 6-cm tissue culture plates, the cells were infected with viruses using 1 ml of virus solution, to which 10 μl of 1 mg/ml Polybrene was added, produced by introducing pMX-neo into packaging cells. 3 ml 10% FCS DMEM was added after 4 hours and cultivation was continued until confluence was reached. Following one passage, the system was cultured until 50% confluence was reached in DMEM supplemented with Polybrene at a final concentration of 2 $\mu\text{g}/\text{ml}$. Then, the medium was exchanged and cultivation was continued for 2 to 3 days in 2 ml of DMEM. The supernatant was passed through a 0.45 μm filter, infected newly to NIH3T3 cells, and selectively cultivated in DMEM containing G418 (neo). If retroviruses having the ability to replicate were produced, a G418 resistant colony should have appeared. However, such colonies were not detected.

[Example 10] Examination on the stability of Plat-E cells compared to those of Bosc23 cells and Phoenix-E cells

30 The present inventors compared Plat-E cells in its initial progress to Bosc23 cells and Phoenix-E cells in terms of its ability or inability to produce retroviruses at a high titer with long-term stability by transient transfection. The cultivation conditions for the three packaging cell lines were as follows:

35 According to the manufacturer's instructions, the Bosc23 cells were proliferated in DMEM containing GPT selective reagent (Specialty Media,

Lavallette, NJ, USA) supplemented with 10% fetal bovine serum. Phoenix-E cells were classified by FACS using the expression of CD8 as an index, were cultured for one week in DMEM containing hygromycin (300 µg/ml) and diphtheria toxin (1 µg/ml) supplemented with 10% fetal bovine serum, and then were transferred to DEME supplemented with 10% bovine fetal serum which doesn't contain hygromycin and diphtheria toxin. Plat-E cells were maintained all the time in DEME containing blasticidin (10 µg/ml) and puromycin (1 µg/ml) supplemented with 10% fetal bovine serum. The infection efficiency of retroviruses produced from Bosc23 diminished within 3 months and that of retroviruses produced from Phoenix-E cells diminished similarly. On the other hand, retroviruses produced from Plat-E retained an average titer of approximately 1×10^7 /ml to NIH3T3 cells for at least 4 months under conditions of drug selective pressure and an infection efficiency of 75% or more (maximum of 99%) to BaF/3 cells when they were transfected transiently.

To compare the expression level of Gag-pol and env mRNA in Plat-E, Bosc23, and Phoenix-E packaging cell lines, Northern blot analysis was performed using cells cultured for 3 weeks. The expression level of Gag-pol and env mRNA in Plat-E cells were 4-fold and 10-fold more, respectively, compared to other cell lines.

RT activity in the cell lysate was also analyzed. The RT activity in Plat-E cells was detected to be at least twice as high as that in Bosc23 and Phoenix-E cells. Furthermore, the expression level of the env protein evaluated by antibody staining using antibodies raised against the env gene product was considerably higher than that in Bosc23 and Phoenix-E cells.

Therefore, it was indicated that Plat-E cells could produce retroviruses at high titer with long-term stability.

30 Industrial Applicability

A virus-producing cell that sustains the ability to produce infectious viruses at high titer even after long term passages is provided according to the present invention. Additionally, a method for producing infectious viruses at high titers using the virus producing cells is also provided. The use of retroviral packaging cells of this invention enables the stable provision of retroviruses

with high titers. In addition, by minimizing the viral genome to be included in the packaging cell, the inventors successfully lowered the possibility of the emergence of undesirable recombinant viruses, such as replication competent retroviruses (RCR). Therefore, the 5 retroviral packaging cells of this invention serve as powerful tools for producing retroviral vectors in fields of biology and medical research, and are useful for producing gene transfer vectors used in gene therapy.

2019 RELEASE UNDER E.O. 14176

CLAIMS

1. A cell used for the production of retroviruses, wherein the cell
5 has an expression construct comprised of a DNA encoding retroviral structural proteins operably linked downstream of an EF1 α promoter.
2. The cell according to claim 1, wherein the DNA encoding retroviral structural proteins are DNA encoding proteins selected from the group consisting of gag, pol, and env.
10
3. The cell according to claim 2 wherein the retroviral structural proteins expressed comprise gag, pol, and env.
4. The cell according to claim 3, which has a first expression construct expressing gag and pol, and a second expression construct expressing env.
15
5. The cell according to claim 3 or 4, wherein the env is derived from either an ecotropic retrovirus or amphotropic retrovirus .
20
6. The cell according to any one of claims 1 to 5, wherein a Kozak's consensus sequence is placed upstream of a translation initiation codon of the DNA encoding the retroviral structural proteins in the expression construct.
25
7. The cell according to any one of claims 1 to 6, wherein the DNA encoding the retroviral structural proteins is bound to a DNA encoding a selective marker via an IRES sequence.
30
8. The cell according to any one of claims 1 to 7, wherein the DNA encoding the retroviral structural proteins is substantially free from virus genome-derived DNA with the exception of the protein coding region.
35
9. The cell according to any one of claims 1 to 8, wherein the cell

is derived from 293 cells.

10. The cell according to claim 9, wherein the cell is derived from 293T cells.

5

11. The cell specified by the accession No. FERM BP-6737 or FERM BP-6977.

12. A method for producing a retrovirus, comprising the step of: introducing a retroviral vector DNA lacking at least one of the genes encoding a viral structural protein into the cell of any one of claims 1 to 11.

10

13. The method according to claim 12, wherein the retroviral vector DNA lacks all of the genes encoding gag, pol, and env.

15

14. The method according to claim 12 or 13, in which a foreign gene is included in the retroviral vector DNA.

20

15. A retrovirus produced by the method of any one of claim 12 to 14.

ABSTRACT

A virus-producing cell sustaining the ability to produce viruses at high titer is successfully constructed by expressing the virus structural gene under the regulation of EF1 α promoter. In this virus-producing cell, the virus structural gene is ligated to a selection marker gene via IRES and domains other than the protein coding domain are eliminated from the DNA encoding virus structural proteins. Thus, reduction of the titer due to cell passages can be prevented and emergence of wild type viruses caused by unfavorable recombination of the virus genome can be inhibited.

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled PACKAGING CELL, the specification of which:

- is attached hereto.
- was filed on _____ as Application Serial No. _____ and was amended on _____.
- was described and claimed in PCT International Application No. PCT/JP00/03557 filed on June 1, 2000 and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
PCT	PCT/JP00/03557	June 1, 2000	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Japan	11/154364	June 1, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Japan	2000-17831	January 21, 2000	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

7
Janis K. Fraser, Ph.D., J.D., Reg. No. 34,819
Harold H. Fox, Reg. No. 41,498
Timothy A. French, Reg. No. 30,175
Anita L. Meiklejohn, Ph.D., Reg. No. 35,283

J. Peter Fasse, Reg. No. 32,983
John W. Freeman, Reg. No. 29,066
John F. Hayden, Reg. No. 37,640

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804

Combined Declaration and Power of Attorney
Page 2 of 2 Pages

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

1-00

Full Name of Inventor: TOSHIO KITAMURA

Inventor's Signature: Toshio Kitamura Date: February 18, 2002
Residence Address: Tokyo, Japan JPX
Citizenship: Japan
Post Office Address: 6-16-20-406, Shirokane, Minato-ku
Tokyo 108-0072 JAPAN

2-00

Full Name of Inventor: SUMIYO MORITA

Inventor's Signature: Sumiyo Morita Date: February 25, 2002.
Residence Address: Tokyo, Japan JPX
Citizenship: Japan
Post Office Address: 5-11-9-202, Minamiazabu, Minato-ku
Tokyo 106-0047 JAPAN